PROVE Endurance Car Front Suspension

This document details the collaborative Mechanical Engineering Senior Project with Cal Poly PROVE Lab on PROVE Lab’s Project 2; an electric vehicle designed to travel 1000 miles on a single charge. Logan Simon, Justine Kwan, and Lauren Williams are given the challenge of designing an innovative proof of concept front suspension suspension for this vehicle. After detailed research of new suspension systems, it was determined that the innovative nature could be in the form of unique manufacturing methods, materials use, or mechanical design. At this point in time, this vehicle is a purely conceptual design with no concrete requirements. Therefore engineering specifications were generated based on vehicles of similar size and function, such as PROVE Lab Project 1, Tesla’s Roadster, and the BMW z4. These specification included vehicle weight, speed, vertical travel, system weight, travel speed, and track width. Since this car is aimed to travel 1000 miles on one charge, efficiency is a big concern for the design. From ideation, the three suspension configurations of interest were MacPherson, double wishbone, and multi-link. A decision matrix was created to evaluate these designs based on design requirements, resulting in the selection of the multi-link configuration. However, after further investigation it was decided that a double wishbone configuration would provide nearly equal performance and be much more manageable of a task on the senior project time frame, compared to multi-link. The focus of the project then shifted to innovative manufacturing methods. Carbon fiber was chosen as the material to be used due to its lightweight nature, its accessibility through PROVE lab, and its lack of usage in a suspension system thus far. The upright would provide the most weight savings, so it was designed as a carbon fiber sandwich panel. Computer analysis of the system included SolidWorks FEA, Tsai Wu Failure Analysis, and ANSYS composite analysis to verify Tsai Wu. Four destructive tests were performed to validate the analysis and to determine the number of plies to be used for the final part. With all four tests passing the minimum load requirements with a factor of safety above 1, 16 plies per laminate was chosen and with an additional 8 plies around the edges. The final system proves that a carbon fiber suspension that is structurally sound for maximum loading cases and that cuts weight down to 4.3 pounds is possible. The full non-destructive test will be performed by the PROVE Project 2 team in the future, unassociated with this senior project

Aspects of physical and chemical alterations to proteins during food processing - some implications for nutrition

In this paper, we give an overview of our research exploring the impact of physical and chemical processing on food proteins. There are three themes, applied to the proteins of wheat, soya, egg and dairy foods. Firstly, the impact of the Maillard reaction on food proteins is discussed, with a particular focus on how the reactions might be harnessed to manipulate food texture. Secondly, the potential of enzymatic protein-protein crosslinking is considered, especially the enzyme transglutaminase. Thirdly, the broader question of how the aggregation of proteins within a food is altered by chemical and physical modification and how, in turn, this might impact on the overall nutritional quality of the food is considered

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Alirocumab and cardiovascular outcomes after acute coronary syndrome

BACKGROUN

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

BACKGROUN